11β-Hydroxysteroid Dehydrogenase Type 1, But Not Type 2, Deficiency Worsens Acute Inflammation and Experimental Arthritis in Mice
Open Access
- 1 January 2012
- journal article
- research article
- Published by The Endocrine Society in Endocrinology
- Vol. 153 (1), 234-240
- https://doi.org/10.1210/en.2011-1398
Abstract
Glucocorticoids profoundly influence immune responses, and synthetic glucocorticoids are widely used clinically for their potent antiinflammatory effects. Endogenous glucocorticoid action is modulated by the two isozymes of 11β-hydroxysteroid dehydrogenase (11β-HSD). In vivo, 11β-HSD1 catalyzes the reduction of inactive cortisone or 11-dehydrocorticosterone into active cortisol or corticosterone, respectively, thereby increasing intracellular glucocorticoid levels. 11β-HSD2 catalyzes the reverse reaction, inactivating intracellular glucocorticoids. Both enzymes have been postulated to modulate inflammatory responses. In the K/BxN serum transfer model of arthritis, 11β-HSD1-deficient mice showed earlier onset and slower resolution of inflammation than wild-type controls, with greater exostoses in periarticular bone and, uniquely, ganglion cysts, consistent with greater inflammation. In contrast, K/BxN serum arthritis was unaffected by 11β-HSD2 deficiency. In a distinct model of inflammation, thioglycollate-induced sterile peritonitis, 11β-HSD1-deficient mice had more inflammatory cells in the peritoneum, but again 11β-HSD2-deficient mice did not differ from controls. Additionally, compared with control mice, 11β-HSD1-deficient mice showed greater numbers of inflammatory cells in pleural lavages in carrageenan-induced pleurisy with lung pathology consistent with slower resolution. These data suggest that 11β-HSD1 limits acute inflammation. In contrast, 11β-HSD2 plays no role in acute inflammatory responses in mice. Regulation of local 11β-HSD1 expression and/or delivery of substrate may afford a novel approach for antiinflammatory therapy.Keywords
This publication has 38 references indexed in Scilit:
- Upregulation of 11β-hydroxysteroid dehydrogenase 1 in lymphoid organs during inflammation in the ratThe Journal of Steroid Biochemistry and Molecular Biology, 2011
- Novel Fat Depot–Specific Mechanisms Underlie Resistance to Visceral Obesity and Inflammation in 11β-Hydroxysteroid Dehydrogenase Type 1–Deficient MiceDiabetes, 2011
- Pharmacology of glucocorticoids in rheumatoid arthritisCurrent Opinion in Pharmacology, 2010
- The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insightsMolecular and Cellular Endocrinology, 2010
- Hypothalamic‐Pituitary‐Adrenal Axis Abnormalities in Response to Deletion of 11β‐HSD1 is Strain‐DependentJournal of Neuroendocrinology, 2009
- 11β-Hydroxysteroid Dehydrogenases Are Regulated during the Pulmonary Granulomatous Response to the Mycobacterial Glycolipid Trehalose-6,6′-DimycolateNeuroimmunomodulation, 2009
- Inhibition of 11ß-hydroxysteroid dehydrogenase type 1 as a promising therapeutic targetDrug Discovery Today, 2007
- Local Amplification of Glucocorticoids by 11β‐Hydroxysteroid Dehydrogenase Type 1 and Its Role in the Inflammatory ResponseAnnals of the New York Academy of Sciences, 2006
- Expression of 11β-hydroxysteroid dehydrogenase type 1 permits regulation of glucocorticoid bioavailability by human dendritic cellsBlood, 2005
- The role of adrenocorticoids as modulators of immune function in health and disease: neural, endocrine and immune interactionsBrain Research Reviews, 1997